Abstract
Protein-ligand binding governs enzymatic catalysis, metabolic homeostasis, and therapeutic modulation. Thus, the accurate prediction of these interactions underpins modern rational drug discovery. However, existing deep-learning frameworks largely operate as black-box predictors that fail to resolve the individual residues mediating binding or decode the fundamental non-covalent forces that drive molecular recognition. To address these limitations, we present ExplainBind , an interaction-aware framework that predicts binding likelihood, localizes specific binding residues at single-amino-acid resolution rather than coarse pocket-level regions, and decodes the underlying non-covalent interaction patterns, all zero-shot, without requiring prior three-dimensional structural inputs. To support residue- and interaction-level training and evaluation, we construct InteractBind , a protein–ligand benchmark with residue–atom interaction maps. Simultaneously, benchmarking experiments demonstrate that ExplainBind consistently outperforms state-of-the-art baselines across diverse protein and ligand spaces, maintaining high precision when generalized to entirely novel sequences and chemical scaffolds. When applied to two unseen therapeutic targets, ExplainBind successfully ranks potent angiotensin-converting enzyme (ACE) inhibitors and clarifies differences in their potency via affinity-stratified interaction landscapes. Furthermore, we demonstrate the prospective utility of ExplainBind by discovering novel inhibitors and activators of L-2-hydroxyglutarate dehydrogenase (L2HGDH) through wet-lab validation, with mechanistically distinct interaction profiles providing a clear molecular rationale for their divergent functional outcomes. Collectively, these results establish ExplainBind as a powerful, generalizable tool for mechanistically informed, interpretable drug discovery.
Full text
2,265 characters
· extracted from
oa-html
· click to expand
Abstract
Protein–ligand binding governs enzymatic catalysis, metabolic regulation, and therapeutic modulation, and its prediction underpins drug discovery. However, existing AI approaches broadly function as black-box predictors that cannot resolve which residues mediate binding or which non-covalent forces drive molecular recognition. We present ExplainBind, an interaction-aware framework that predicts binding likelihood, localizes specific binding residues rather than coarse pocket-level regions, and decodes the underlying non-covalent interaction patterns, all without requiring three-dimensional structural inputs. ExplainBind consistently outperforms representative baselines across proteins and ligands ranging from closely related to highly novel sequences and scaffolds. Applied to two unseen targets, ExplainBind successfully ranks potent angiotensin-converting enzyme (ACE) inhibitors and explains potency differences via affinity-stratified interaction landscapes, and prospectively discovers both inhibitors and activators of L-2-hydroxyglutarate dehydrogenase (L2HGDH), with mechanistically distinct interaction profiles rationalizing their divergent functional outcomes, establishing it as a broadly applicable tool for mechanistically informed drug discovery.
Competing Interest Statement
The authors have declared no competing interest.
Footnotes
The revised manuscript expands the evaluation of ExplainBind beyond binary binding prediction to include binding-site localization and non-covalent interaction prediction. Compared with the previous version, it now evaluates representative baselines across binding prediction and residue-level localization, revealing that high binding classification performance does not necessarily translate into accurate binding-site identification. The revision also introduces an interaction-type-specific evaluation using Interaction Hit Rate (IHR) to quantify recovery of individual non-covalent contacts at the residue-atom level. In addition, the abstract, introduction, results narrative, figures, and mechanistic analyses have been substantially revised, with expanded discussion of interaction-aware supervision, comparison with structure-based models, and updated ACE and L2HGDH validation analyses.
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.